Clinical Management of Ovarian Hyperstimulation Syndrome with Furosemide at a Tertiary Referral Center—A Retrospective Data Analysis
Journal of Clinical Medicine · 21.08.2026 · 15 (16) · 6468
DOI: 10.3390/jcm15166468 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.08.2026. Verfasst von Daniel Mayrhofer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Clinical Division of Gynaecologic Endocrinology and Reproductive Medicine, Medical University of Vienna, 10…. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objective: Ovarian hyperstimulation syndrome (OHSS) is a severe complication during controlled ovarian hyperstimulation. Ascites and consecutive hemoconcentration may lead to potentially life-threatening complications like thromboembolic events and the need for intensive care. The use of diuretics is widely used to treat ascites in non-OHSS patients. The aim of this study was to assess whether the use of furosemide in the treatment of OHSS was associated with a higher rate of complications compared to the literature.
Methods
In this retrospective cohort study, 502 cases treated from January 2005 to June 2023 for OHSS at the Medical University of Vienna were evaluated regarding the distribution of OHSS severity, average duration of treatment, types and frequency of complications associated with antidiuretic treatment, and predictive factors for paracentesis.
Results
The median AMH levels were 5.7 ng/mL. An antagonist protocol was used in 80% of stimulations. Human Chorionic Gonadotropin trigger was used in 80% of stimulations, with 71.7% of cases being early-onset. The incidence dropped from 8.4% (2006 to 2016) to 3.3% (from 2015 to 2023). The median duration of inpatient treatment was seven days, with about 75% of patients receiving furosemide as a diuretic treatment. Ascites drainage was necessary in 27.9%. None of our patients developed a thromboembolic complication following the furosemide treatment.
Conclusions
During the study period, the incidence of OHSS declined, most probably as a result of advances in ovarian stimulation protocols and freezing strategies. In moderate to severe OHSS, standardized diuretic treatment with furosemide was not associated with additional thromboembolic complications as long as patients remain normovolemic.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, Clinical Division of Gynaecologic Endocrinology and Reproductive Medicine, Medical University of Vienna, 1090 Vienna, Austria.
- Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
ORCID-Profile: Daniel Mayrhofer, Marlene Hager, Johannes Ott, Julian Marschalek
Zitieren
APA
Mayrhofer, D., Walch, K., Hager, M., Künz, R., Hoeltz, A., Marculescu, R., Ott, J., & Marschalek, J. (2026). Clinical Management of Ovarian Hyperstimulation Syndrome with Furosemide at a Tertiary Referral Center—A Retrospective Data Analysis. Journal of Clinical Medicine, 15(16), 6468. https://doi.org/10.3390/jcm15166468
Vancouver
Mayrhofer D, Walch K, Hager M, Künz R, Hoeltz A, Marculescu R, et al. Clinical Management of Ovarian Hyperstimulation Syndrome with Furosemide at a Tertiary Referral Center—A Retrospective Data Analysis. Journal of Clinical Medicine. 2026;15(16):6468. doi:10.3390/jcm15166468
BibTeX
@article{Mayrhofer2026,
author = {Mayrhofer, Daniel and Walch, Katharina and Hager, Marlene and Künz, Rebecca and Hoeltz, Alina and Marculescu, Rodrig and Ott, Johannes and Marschalek, Julian},
title = {Clinical Management of Ovarian Hyperstimulation Syndrome with Furosemide at a Tertiary Referral Center—A Retrospective Data Analysis},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {16},
pages = {6468},
doi = {10.3390/jcm15166468}
}
EUVIMED